Drug intelligence / Profile preview

FND-4b

Development stage: Preclinical
Lead developer: University of Kentucky
Modality: Small Molecules
Administration: Oral

Overview

FND-4b (1-(3-chloro-4-((trifluoromethyl)thio)phenyl)-3-(4-(trifluoromethoxy)phenyl)urea) is a novel fluorinated N,N'-diarylurea compound developed at the University of Kentucky. It acts as a potent activator of AMP-activated protein kinase (AMPK) at low micromolar concentrations. Preclinical studies have demonstrated that FND-4b inhibits cell proliferation, arrests the cell cycle, and induces apoptosis in colorectal cancer (CRC) and triple-negative breast cancer (TNBC) models, both as a monotherapy and in combination with other therapeutic agents.

Other names: 1-(3-chloro-4-((trifluoromethyl)thio)phenyl)-3-(4-(trifluoromethoxy)phenyl)urea

Targets

AMPK (Adenosine monophosphate–activated protein kinase)

Beyond the preview

Go deeper on FND-4b.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FND-4b.

Explore the full profile